Azilsartan Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 40 mg
Reference Brands: Edarbi(EU), Takarta(US)
Category:
Hypertension
Azilsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from constricting blood vessels, leading to vasodilation. It lowers blood pressure, reduces stroke risk, and supports cardiovascular health. Benefits include effective hypertension control, improved heart function, and long-term protection against cardiovascular events.
Azilsartan tablets is available in Tablets
and strengths such as 40 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Azilsartan tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Azilsartan tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Azilsartan tablets, marketed as Edarbi in the EU and Takarta in the US, are approved for hypertension management. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for approval, while the EMA ensures compliance with regional safety and quality standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Supporting regional compliance facilitates timely approval, safe use, and global availability of azilsartan tablets, helping patients worldwide control blood pressure and reduce cardiovascular risks effectively.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing